Ladies and gentlemen, good day, welcome to the IKS Health Q4 FY 2026 earnings conference call hosted by ICICI Securities. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing star then zero on your touchtone phone. Please note that this conference is being recorded. I now hand the conference over to Ms. Seema Nayak from ICICI Securities. Thank you, and over to you, ma'am. Good morning, ladies and gentlemen. Thank you for joining us today on Q4 FY 2026 earnings call of IKS Health. On behalf of ICICI Securities, I would like to thank the management of IKS Health for giving us the opportunity to host this call. Today, we have with us Mr. Sachin Gupta, Founder and CEO, Ms. Nithya Balasubramanian, CFO, and Mr. Saransh Mundra, Head of Investor Relations. I turn it over to Mr. Saransh for his brief statement and to take the proceedings forward. Thank you. Over to you, Saransh. Thank you, Seema. Good morning to everyone on the call. Welcome to our earnings call for the fourth quarter and year ended March 31st, 2026. I'm Saransh Mundra, VP Finance. We hope you've had an opportunity to review the earnings release and the investor presentation that we issued. Before I hand over to Sachin and Nithya, let me begin with a safe harbor statement. As part of our prepared remarks and during Q&A, we may make certain statements which are forward-looking and involve significant uncertainty. IKS doesn't take any responsibility to update such forward-looking statements. Your discretion is warranted while making any investment decisions. Over to you, Sachin. Thank you, Saransh. Good morning and good evening, everyone, depending on where you're joining from. It is my pleasure to join you all today to talk about our performance for Q4 fiscal 2026 and the full year ending in December 31st, 2026. I think this is our sixth earnings call since we went public in December 2024. Excited to be with you all today. We'll start off with a quick recap, obviously, of the overall business and the business model. Talk about some of the key strategic drivers for success in our business and give you a little update on how those are faring. Talk a little bit specifically about how we are leveraging AI most effectively to actually make it a differentiated moat in the business as we continue to grow. Dive into, obviously, our financial performance for Q4, as well as for fiscal 2026. I will then invite Nithya to make some remarks, additional remarks on our financial performance, and we will then turn it over for questions and discussion. With that, obviously, as you know, IKS is in the business of delegating chore tasks for healthcare providers in the U.S. It's probably the largest industry in the world at $5 trillion+, and it creates a very large TAM of north of $260 billion that U.S. healthcare is spending on all of these tasks that can be delegated or outsourced by our platform. Of that $260 billion TAM, as you might recall, the outsourced TAM today is about $35 billion, and the overall TAM of $260 billion is growing at about 8%, and the outsourced TAM is growing faster than the overall TAM at about 12%. Just to recap, any time IKS grows on a year-on-year basis for any period faster than 12%, we're gaining market share. Of course, we don't want to be in a situation where we're not growing faster than 12% because that would mean losing market share. In general, that's a sort of a good marker to keep in mind. Today, IKS has a little north of 600 clients, or client organizations if you would, which are provider organizations. You might recall same time last year, that number was 700+, and maybe a couple of years ago when we acquired AQuity, that number was closer to 900. As we've always maintained, we have been cutting down the tail of small clients that we had inherited through AQuity because our business in our traditional model works best when we're servicing large clients. That number of 600 odd reflects the paring that has happened over the last year. As I've always stated, we feel like we'll eventually end up at some number between 500 and 600. We're more or less close to done on some of that tail cutting that we had embarked on as we acquired AQuity. Excitingly, 90% of our revenues come from repeat customers, and we have a very healthy vintage of our top 10 and top five customers on an average being 5+ years. Our headcount as of March 31st, 2026 is 13,331 people, of which 1,981 are clinically trained staff. Just so that people know, that headcount as of March 31st, 2025 was actually a bit higher. Sorry, a bit lower, but it was about 5.3% lower at 12,661. Our headcount has grown over this period from 12,661- 13,331, which is about a 5% growth in headcount, which obviously reflects the non-linearity of our business model because our revenue growth is significantly higher than the headcount growth, which we'll cover in our Q4 financials in a bit more detail. Of our 13,331 people, the fastest-growing component of our workforce is actually our technology workforce of now 550 employees that is focused on building all of our proprietary technology that enables our platform. And a large part of that workforce now tends to be the AI engineering workforce in addition to the data science workforce. Then, we've also constantly been growing our sales and marketing endeavors and our investments there, and our sales and marketing headcount now stands at 66 FTEs and growing. To, you know, just to take a quick recap so that we all understand the competitive landscape. When you have such a large TAM of $260 billion and the outsourced TAM of $35 billion growing at 12%, you naturally expect a significant amount of competition in the ecosystem. Just to recap and calibrate on our language, there are generally three broad genres of competition that are competing for this TAM. Those three broad genres are first, what I call system of record companies, which are nothing but electronic health record vendors that were created back in the early 2000s as the U.S. government gave money to providers to roll out these electronic health record systems that, one, store all of the patient data for the care that is being provided by these caregiving organizations. Two, they have some workflows as it relates to the patient's journey with the caregiving organization. Call them sort of the core operating system of healthcare providers. Those are the electronic health records. What these electronic health records did when they were rolled out was, in addition to becoming patient data stores, unfortunately, unintended consequence, they made these healthcare providers and the administrators of these healthcare provider organizations almost data entry operators, right? They ended up having to start spending a lot of their time entering data and maintaining data in the electronic health record versus spending their time managing patients. That, in addition to that, and a number of regulatory challenges in U.S. healthcare, given how regulated it is, it created a whole bunch of tasks, which we call chore tasks, that the providers are getting distracted with and their administrators are getting distracted with. To, in order to do those chore tasks efficiently and not get the providers distracted by those chore tasks, that created the need for what we call systems of action that would take all these chore tasks and free the providers and their administrators up from those tasks. We call those systems of action that can do that. In the system of action category, there are two types. There are point solution systems of interaction, which essentially solve for one or two or three of these tasks, because the individual TAM of each of these tasks is so large when the total TAM is $260 billion, right? They, I call them point solution systems of action. Then there are very few rare organizations that are drinking from the Kool-Aid of the thesis that eventually large provider organizations can't be in this point solution hell of buying multiple point solutions, integrating them themselves. Eventually, this market will gravitate more and more towards what I call platform systems of action, which is what really is where we have a comprehensive platform that takes all of these tasks at once. When you do that, actually, one, we're able to take accountability for the outcomes for these tasks. You know, the provider organizations have one entity to hold accountable for the cost and quality outcomes for these tasks, and revenue outcomes for these tasks. And then, second, the value of these tasks done together by one platform compounds because all of these tasks are interconnected in nature. That's what I call the platform system of action. Those are the three genres of companies. System of records that were core legacy systems that are now waking up with generative AI and agentic AI and thinking they should become the platform system of action. Rare platform system of action companies like us, and then a whole bunch of large point solution, large number of point solution, systems of action. I think that language is somewhat important as we continue to think about IKS's positioning in this very large, growing market. Moving forward, in order to capture a significant share of this very large TAM, IKS as a platform system of action has laid out five key strategic pillars of execution for ourselves. I'll talk a little bit about each of the five pillars. There's obviously going to be a sixth pillar that will likely get added here, if we are fortunate enough to close the transaction that we'd announced a few weeks ago, the acquisition of TruBridge, because obviously the integration of TruBridge and our massive opportunity in the rural healthcare market will become another important pillar of execution, which will then have actually some cross-leverage in our core large physician group market as well. For now, let's focus on these five pillars. The first one is, remember when we started building our platform system of action 18, 19 years ago, it was a human-led tech-in-the-loop kind of endeavor because at that time, technology was not advanced enough, and healthcare was too fragmented, and there were no standardization of workflows for technology to truly be able to eliminate all these tasks. We started with a human-led tech-in-the-loop model, which over the timeframe of, say, 2010 to maybe 2020, became a lot more tech-led and human-in-the-loop, where the humans started to go from doers of tasks to auditors of tasks. Now with the advent of generative AI and really specifically agentic AI, back in about 2022, 2023 maybe, we started moving from a tech-led human-in-the-loop to really a AI-native agentic platform manifest, where our ambition obviously is to move as many of these features, which are the tasks that we do for these providers of our platform, to a fully autonomous, agentic manifest. That's the first key pillar of our five key strategic pillars that we are trying to execute on. Happy to note that we continue to make some very significant progress on this pillar. As you note, you might have noted through our various releases over the course of last quarter, we've launched an interconnected agentic workflow for autonomous clinical documentation, coding, and prior authorization. These three tasks tend to be the tasks that cause some of the greatest friction, for want of a better term, in the patient's journey with the provider and in the provider's workflow. Really important to alleviate the burden of these tasks from the provider's workflow. Also, each of these tasks are very related to each other, these done right in an interconnected agentic workflow, they can have a very nice compounding effect on the outcome. We've launched a very exciting version of Scribble, which is our ambient AI scribing product. You might recall we had launched Scribble Now, which was our completely autonomous Ambient AI scribing product. We are now in realization of the fact that, you know, this is a very important construct. The fact is, no matter how good generative AI models get in healthcare, there will always be some edge cases, no matter how good generative AI gets, that will require some level of human-in-the-loop, especially in healthcare, where we cannot afford sorry, hallucinations and inaccuracies. In the case of this Ambient AI scribing, it became apparent to us that a lot of these Ambient AI scribing point solutions, as those got rolled out all over the country in the U.S., one saw that there was a lot of doctors using it. The challenge that one also saw very quickly was that the number of patient visits for which the doctors were using the Ambient AI scribing products was topping off at 50%, 60%. Technically, all the doctors in a medical group or in a hospital system are using it, but if they're only using it for 50%, 60% of their patient encounters, that means 40%, 50% of their burden is still lying there. As we dug in deeper into that, we understood that this whole phenomena of, you know, there are certain types of patients' visits where the Ambient AI scribing just does not produce the type of outcome the doctor needs, and the doctor ends up having to do too much of the editing of the product themselves. Given our legacy of tech-led and human-in-the-loop, we've actually now launched a new multivariate product of our Ambient Scribing solution called Scribble Select, I think it's the only product in the industry that exists like that allows the doctor to choose different variants of Scribble for different type of patient encounters. For some of the very complex patient encounters, they might choose the Scribble version with some human in the loop, where there's a clinician in the loop that oversees the documentation, edits the documentation, and cleans it up before it goes to the doctor. For some of the more simpler visits, they might use the fully autonomous Ambient AI scribing product called Scribble Now. Having such a multi-variant option for each doctor is actually already starting to show in our early implementations a very fundamentally different level of utilization by these doctors. Very excited about the launch of Scribble Select. Again, it signals our very perhaps pragmatic approach to leveraging gen AI effectively where it can drive autonomy, but left keep giving the human in the loop where it can truly eliminate the burden for the physician users. In addition to that, we continue to make advances in the autonomous coding endeavors that we have, where we've already developed high levels of accuracy for two of the specialties and will continue to expand. Super excited to launch MyCare Hub over this last quarter, which is really a multi-agent orchestration technology across several patient engagement features like scheduling optimization, patient onboarding, eligibility, and benefits verification, etc. Again, significant progress across several features in this endeavor to move into an AI native, agentic platform manifest. On the second pillar of our integration of the AQuity acquisition, happy to note that the first two dimensions of that are now more or less complete. I think AQuity and IKS really operate like one organization now, both in terms of how we are operating tangibly, but also I think culturally. There was obviously a significant margin opportunity from the AQuity acquisition by transforming their operating model from a heavy human-led, U.S.-based operating model to a true, tech-led and offshore-enabled operating model for the human-in-the-loop part. That is now more or less complete, which obviously you've seen in our margin expansion over the last couple of years. Then, the third big vector was the cross-sell into the large AQuity customer install base. Granted, that took us longer than we had originally planned, and that's predominantly because we made some mistakes in hindsight in how we went to market in some of the large health system-owned groups in the legacy customer base of AQuity. The mistake we made was that we went with our big platform pitch to these buyers, of the large health system-owned provider groups. The reality was that the buyers in the AQuity customer base there were not the C-suite buyers. They were buyers that were really focused users of certain point solutions or certain tasks. For them, the large platform pitch seemed intellectually interesting, but they had nowhere to take it because they were not the decision-makers for this. We thought we'd be able to leverage those people to elevate the conversation to the C-suite, which took longer than we expected. We also learned. Over a period of time, the large health system-owned groups today do not have the appetite for a full platform manifest, even as they intellectually are intrigued by the idea, and both from a change management perspective, how they're internally organized. We actually then pivoted our strategy where we are going with, for the mid-size, health system-owned medical groups, we're still going with the platform manifest and the platform-based GTM. For the large health systems, now we have pivoted our go-to-market where we are resorting to a pure land and expand strategy, where there are certain point solutions that they are very interested in buying today, i.e., the RCM features, the coding features, perhaps the features around patient access. We're going to market specifically to those large health system-owned groups with those features and then expand over a period of time. The mid-size health systems, we're going with the full platform idea. You know, happy to note that one of the successes of that strategy is manifested in this quarter where a large health system, a top five health system, has chosen to expand their relationship with us in the dimensions of RCM and value-based care. Yet, at the same time, we've announced a very significant full platform deal with a mid-size health system that also came from the AQuity customer base. I feel like we've now figured out the plot to truly unlock that cross-sell motion in the AQuity customer base. Of course, the proof will be in the pudding as we continue to manifest that strategy over the next several quarters and years. Driven by this differentiated strategy, where for the large health systems, the go-to-market is still more point solution oriented because of the land and expand motion. We need to be number one or two or three in each of those point solutions that the large health systems are buying, namely RCM, coding, patient access, while being the only company that has the full platform manifest that other segments of the market are loving. We actually believe eventually the large health system markets will also love the platform manifest, but they're not quite there yet. That means, we needed to be like I said, that number one or two or three in some of those point solutions. Happy to note as our third pillar that we've really been able to make progress. Today we are number one in AI-driven RCM as recognized by Black Book. We're a top performer in ambulatory RCM as recognized by KLAS, K-L-A-S. As you know, KLAS is probably sort of the Gartner equivalent of IT services, if you would, they're the Gartner equivalent of healthcare, if you would. You know, very happy to note that we're very close to the number one provider in the ambulatory RCM category by KLAS, and continue to have significantly good ratings in both documentation and coding by both Black Book and KLAS. Good progress there. I already spoke a little bit about our differentiated growth strategy, which now is stratified between a platform go-to-market for mid-size health system-owned groups, as well as independent single specialty and multi-specialty groups. For the large health systems, focus on entree through two or three point solutions and then expand from there. Last but not the least, a very important pillar of our strategy is over a period of time, what would our moat be? I think our moat would be two-pronged. One, we would be the one of the only comprehensive platform systems of action in the country. Number two, when a platform system of action is actually able to align its outcomes with the provider's outcomes, it becomes even more appealing. That's where, you know, when we take accountability for outcomes and execute to those outcomes like we have done, recently in certain deals, you know, like we saw the $3 million NEVA earnings in Palomar from our performance there in the year 2025, that makes the value proposition even more compelling. As we progress here, if we're able to truly demonstrate this ability to produce transformative financial outcomes, even as we are making the administrative burdens of physicians lesser, that would put us in a whole different category as a platform system of action, and that continues to be our fifth key pillar of execution. Happy to note that I think we have fairly good progress across each of those five pillars. As we've done that over these last several months, it's always good to see that we're also getting some recognition for it. We were recognized as one of the best users of AI in healthcare and life sciences. If you go to the next slide, Saransh, please. Then, you know, one of the things that we've always been proud of is the fact that 45% of our workforce is women, and gender diversity is a really important aspect in our business. If you can go to the previous slide, please, Saransh. Previous, yes. One thing IKS is really proud of is not only is 45% of our workforce women, but even when you look at our leadership, you know, there's a very significant mix of women leaders in our leadership. So that being recognized, is important. You know, where you have the likes of Nithya, our CFO, Manisha, our CHRO, Dr. Grace Terrell, our CMO, Katherine, our Chief Marketing Officer, Christi, our Chief Legal and Compliance Officer. We're able to manifest this gender diversity not just at the bottom of the pyramid, but even at the top of the pyramid, which puts us in a very unique position over a period of time. Also now talking a little bit about some of the endeavors that actually accelerated our AI initiatives over this last quarter on some very interesting developments. The first one I want to talk about is Certilytics, which really over a period of time has been an AI-driven innovator on the payer side of the business. You know, as you know, in U.S. healthcare, why revenue cycle is such an important and such an expensive function for payers is because there's this constant cat-and-mouse game that gets played between providers that want to get paid for the care they deliver and payers that have to pay them for the care they deliver, but they're always worried that is the care being delivered appropriate for the type of condition that the patient had? Are we unnecessarily delivering too much care, or are we doing too many surgeries, too many diagnostic tests when the conditions don't demand that, right? That's called utilization in the payer world. The payers are always trying to make sure utilization is proper. There's this constant cat-and-mouse game that happens between the payers and providers. We actually believe that if over a period of time we can get providers and payers to collaborate better, we might actually be able to reduce the friction in this relationship, reduce the cost of revenue cycle on both sides, the payer side and the provider side, and improve the efficiency of the process. In light of that, our partnership with Certilytics has deep experience on how payers, technology is oriented, and with our expertise on the provider technology, our ambition is that barring certain things where there will never be complete collaboration. For example, payers will never put out their APIs as it relates to how they assess whether a claim that is submitted by a provider is appropriate from a utilization perspective. You know, that one is sort of the Holy Grail. It'll never be exposed. If you think about other denials that payers submit, think of denials related to medical documentation or coding. You know, those type of things can easily be eliminated if we can get the payer systems to talk to the provider systems and collaborate through the process. Instead of the dynamic being the providers' people, RCM people versus the payers' RCM people, then the provider's technology versus the payer's technology, and now the provider's AI versus the payer's AI, we can actually create a more collaborative framework that actually reduces the friction in the relationship. We're super excited about this relationship with Certilytics and how it will probably elevate our positioning in this RCM space to a place where not only are we improving how providers conduct their RCM, but we might fundamentally be able to improve outcomes through more collaborative, technology-driven, AI-driven engagement with payers, at least on certain states. Second one that is exciting that we'd already announced also is the strategic acqui-hire of Think DTM, which really was an AI-native and digital services company, where they have now built to the fourth point and launched what we call our MyCare Hub product, which is really an agentic AI self-orchestrating platform that uses an active, aware, and constant multi-agent behavioral algorithm to create this adaptive and autonomous patient engagement operating system. I know that sounds like a lot of jargon, simply put, it's a multi-agent orchestration that again simplifies a lot of the interactions that patients have with a provider organization, be it for scheduling, be it for onboarding, registration, eligibility verification, prior authorization. All of these things create over-the-counter collections for the patient responsibility in the overall reimbursement that the provider is going to get because part of the payment comes from the patient, part of it comes from the insurer or the payer, right? This is a really, really very, very significant AI-driven advancement that we've been able to do with the Think DTM team that's getting some tremendous traction in the marketplace. Last but not the least, obviously continuing to advance our AI-driven revenue cycle as well as our autonomous coding engines. Now both of these, the autonomous coding and revenue cycle engine and MyCare Hub are now actually available in Epic Connection Hub, which becomes a really important aspect of being able to penetrate these products in the large health system environment because the system of record in the large health system environment tends to be Epic. Again, some really strong progress on our AI initiatives over these last few months. Then last but not the least, the comment I'd like to make if you move to the next slide, Saransh, is when you look at the 16 features of our platform, right? 16 odd features of our platform. As you can imagine, at a very individual feature level, we are tracking and driving a path to as much autonomy as is practically possible driven by agentic AI in each of those features. Why do I say as much autonomy as practically possible? Well, first because of the fact that it's healthcare, like I said, for each of these features, almost no matter how good the AI gets, there will always be some edge cases that will need human in the loop. I just wanna clarify that even a 100% autonomy as per this tracking doesn't mean that you've totally eliminated human in the loop. Like I just gave you the example of the Scribble Select product. Even though there is a Scribble Now 100% autonomous Ambient AI scribing tool, in order to use, improve the utilization of that Scribble product and totally eliminating the physician's burden, we're having to create variants with human in the loop so that the actual task can be completed effectively, even though it's heavily enabled by AI, right? Autonomy here might not always mean 100% elimination of human in the loop, but it means largely elimination of human in the loop, right? I just wanted to leave two concepts with everybody. One, we're tracking this by feature and our AI endeavors are built by feature. I just wanna say there's two considerations as to how much autonomous each of these tasks or features can get. One is whether the outcome from that task is a deterministic outcome or a non-deterministic outcome. What does that mean? Basically, generative AI is most successful when there are non-deterministic outcomes in the task. For example, the outcome from Ambient AI scribing is this large narrative clinical documentation. That's not a deterministic outcome. It's not a specific outcome, it's a narrative. Language generation is one of the key strengths of generative AI, right? Generative AI can be very, very useful there. When the outcome is purely deterministic, the generative AI has to be constrained or overlaid by, let's call it symbolic AI models. The neural AI, which is the traditional generative AI, then needs to be combined with symbolic AI which then relies on reasoning based on things like knowledge graphs and ontologies and specific rules and logic. For deterministic outcomes, you have to use a combination of generative AI and the symbolic AI that together can drive higher autonomy. Remember, deterministic versus non-deterministic is a key driver of autonomy. The second piece is, for many of these tasks, you're interacting with entities outside of the provider's organization, and your ability to drive autonomy is also subject to how technology-ready that other enterprise is with which you're interacting, i.e. the payers. It could be the payers, it could be the clearing houses, it could be other providers where you're dealing with tasks like referral management. I just wanted to clarify that those are the things that go into defining how much autonomy can be achieved. It's those types of aspects that are very thoughtfully being put into which of these features get how autonomous over a period of time, as we go down this path. That's a quick thought process as it relates to the various features of our platform. Let's now pivot into the Q4 financial performance. I'm happy to report that we had a very strong quarter of financial performance, perhaps our sixth consecutive quarter of relatively strong financial performance. Revenue grew 18.5% odd year-on-year, coming in at really about INR 857 crores. In constant currency terms, that was about 13% revenue growth, which was in USD. In terms i n INR, it was about 18.5% growth. We now sit with about 450 odd large enterprise customers. Like I said, there were 600 odd customers. Of that, about 450 are the large enterprise-level customers, which is where we see the maximum growth coming from. Our revenue from top 10 customers, it was about INR 452 crores in that INR 857 crores. Like I've said, the vintage for our top 10 and top five customers continues to be north of 5+ years. That revenue of INR 857 crores was delivered using 13,331 employees. Like I was saying earlier, same time last year, we had 12,661 employees. Our growth in employee headcount has been about 5.3%. I want to put this in perspective. For about 13% growth in revenue in constant currency, our headcount growth is only about 5.3%. That constant nonlinearity between revenue growth and people growth is very much evident. Also important to note that if you really look at the December 2025 quarter, which is the previous quarter, our headcount was actually higher than 13,331. If, Saransh, if you were to move to the next slide. You know, essentially, Sorry, just go back. Yeah, it's still this one. Yes. You know, for the 5.2% quarter-on-quarter growth in revenue that we've demonstrated, we've actually declined net headcount from Q3 of FY 2026 to Q4 of FY 2026. Like I was saying, 18.5% year-on-year growth in revenue, 5.2% quarter-on-quarter. That has resulted in an EBITDA of about INR 300 crores, which is about 35% EBITDA. Again, on an 18.5% year-on-year quarterly revenue growth, our EBITDA growth is nearly 33% year-on-year. On a 5% quarter-on-quarter growth, the EBITDA growth is 6.6%. Again, that nonlinearity between revenue growth and people growth and revenue growth and margin growth is easily witnessable here. That also has resulted in a further nonlinearity between revenue growth and profit after tax, where our profit after tax for the INR 857 crores came in at about INR 206 crores, which is about 24%. That was essentially a growth of 39% year-on-year and 12% quarter-on-quarter. Obviously, there's nonlinearity between EBITDA growth and PAT growth also because over the course of the year, we've been constantly paying down debt, and the interest costs are coming down as a result of that. That's why the PAT growth is even more significant than the EBITDA growth. The nonlinearity between revenue and margin growth continues to be witnessed here through the financial performance of this quarter. Saransh, if you were to go back one slide. Happy to announce these three top relationships through the quarter that are of most significance. I'd mentioned a mid-size health system from the legacy AQuity customer base where we were able to cross-sell the entire IKS platform, Holyoke Medical Center. Very proud to announce them as a customer and very excited about this implementation. Also happy to note that in this case, we have not incented them in any way from an outcomes perspective to adopt the full platform. Obviously that sort of demonstration of the value of the full platform is starting to come into play in these deals. Mission Community is an existing customer of ours where we are advancing the relationship from the full manifest of our platform to a very unique AI-driven relationship that will start to drive other efficiencies in the hospital as it relates to predicting ICU utilization, operation theater utilization, nurse utilization, etc. From that be able to use those resources or stretch those resources much more effectively. It's a very unique relationship that actually will allow us to build even more AI-based capabilities from a prediction perspective that can drive significant efficiency in hospital operations. Last but not the least, like I was saying, a top five health system in their AQuity customer base where we very significantly expanded the revenue cycle relationship and the value-based care relationship. This is the evidence of that sort of land and expand approach that, you know, we intend to continue to take with these large health systems. Obviously, all that resulted in a strong growth in earnings per share, which is about 39% year-on-year and 12.3% quarter-on-quarter. Saransh, if you go to slide 11, please. Also continues to produce healthy ROE results, which are north of 30%, in this case 31% odd. The decline year-on-year in the ROE percentage is nothing but based on some revaluation of the base, where, for example, our AQuity holding in Abridge, which is a technology company, got revalued based on their own valuation. You know, based on also the revaluation of some of the assets based on the depreciation of rupee to the dollar, the base got widened, and hence, that shows a minor decline in the ROE percentage. Otherwise, very healthy ROE numbers. All this, obviously, fourth quarter strong performance resulted in a pretty strong performance for the fiscal year 2026 as well. Saransh, if you can go to the next slide. Where revenue came in. Saransh, you can just jump to slide 13, actually. Where revenue came in at INR 3,193 crores, which is nearly a 20% year-on-year growth. And again, the non-linearity being demonstrated where at a 20% year-on-year growth, we have a 38% year-on-year growth in EBITDA. EBITDA coming in at INR 1,091 crores or 34- odd%. A 48% year-on-year growth in PAT, where PAT came in at about INR 721 crores and about 22.6%. All in all, I think, really strong performance and obviously, that resulted in strong performance even on the EPS and ROE parameters, where EPS for the year came in at 43%, which was nearly 48% higher over fiscal 2025. Healthy ROE metrics as demonstrated in slide 14, Saransh. Then, based on all of that, eventually, as you would note, all that has to result in cash flows. Very happy to note that this also resulted in very strong operating and free cash flows. Our operating cash flow growth over the year-on-year basis was nearly 99%, with operating cash flow coming in at INR 863 crores and free cash flows on that INR 721 crores PAT coming in at about INR 612 crores. Very, very healthy metrics as it relates to operating and free cash flows. I want to call out that the improvement in operating and free cash flow ratios. The ratios we track are really OCF to EBITDA and free cash flow to PAT. In FY 2025, our operating cash flow to EBITDA was about 55%. Whereas in FY 2026, it's come in at 79%. Free cash flow in FY 2025 to PAT was about 56%, and in FY 2026, it's come out at 85%. Really healthy numbers as it relates to free cash flow generation, which then has enabled us to reduce our debt over these last couple of years from, I think about INR 850 crores to now standing as of March 31st, 2026, at INR 251 crores. All in all, I think, a strong quarter of performance and a strong year of performance, but, more importantly, perhaps or equally importantly, sets us up for a future based on all the initiatives that we are taking on really becoming an AI native, agentic, platform of interconnected workflows. Perhaps the only platform system of action that exists in the industry today, that is able to align its outcomes with providers' outcomes to drive transformative value. I will pause there for a second, and Nithya, maybe let you comment on some of the key financial metrics that we look at in addition to what I've covered, and then we'll talk a little bit about a couple of other things. Thank you, Sachin. Saransh, if you can go on to the next slide. Yes. Just a few additional nuances on the Q4 numbers. Revenue came in at $95 million. We did see some currency support. On the face of the P&L, you're seeing a Forex gain of INR 35 crores, but please note that there was also a hedge loss of INR 12 crores. The net currency benefit for us was about INR 23 crores. Employee benefit expenses Q4 compared to Q3 was rather flattish in line with the headcount. Other expenses did increase by almost INR 38 crores between the two quarters. The majority of the delta is actually attributable to one-time due diligence and legal fees that are related to the TruBridge transaction. The regulatory approvals are still work in progress, some additional transaction expenses are to be expected in Q1 as well. If you look at finance cost, that has come down sharply compared to Q3. Q3 does have a one-off write-off of the debt issuance cost when we refinance the loan. Our interest rate have come down and so has the finance cost. D&A and interest income are broadly in line with Q3. Our PBT was INR 258 crores and PAT was INR 206 crores. We did report the Western Washington MSO associate loss at about INR 5 crores. Q4 or rather Q1 calendar tends to be seasonally the weakest quarter for U.S. providers. Patient footfalls tend to be very low because of the reset of the insurance and the need to work through the deductible. Patient footfalls were pretty weak. We do expect this to improve in the coming quarters. ETR was about 19% for the quarter and at 20% for the full year. We expect ETR in the range of about 22% for FY 2027. Saransh, if you can go to the next slide. Our EBITDA per employee stands at INR 8.8 lakhs in FY 2026, which is in line with the healthy EBITDA growth that we have seen. Our top 10 customers and top five customers tend to grow pretty strongly. Top 10 customers grew at a very healthy 28% and top five at 18%. Vintage of our top customers also tends to be very healthy, and it remains at the five to six year mark. Sachin's already talked about the FCF yield. In terms of clients with revenue, we have seen a slight decline, and that's simply because some of the AQuity customers that were at more than $1 million saw a little bit of shrinkage as we offshored those customers and offered some discounts. I'll stop my remarks here and hand it over back to Sachin. Sorry to interrupt in between. Sachin, sir, if you're speaking, you're on mute. I'm sorry, I was on mute. I apologize. Thank you. Quickly, I wanna just touch upon our proposed acquisition of TruBridge, which we have spoken extensively about. Just to give everybody a quick recap, we are awaiting the close of that transaction even after we signed the agreement. The idea there is to build the absolute leader, the only integrated system of record and system of action for the rural healthcare market, which is a $162 billion market with 2,200+ hospitals. TruBridge has their EHR in 700 to 800 hospitals, which could be patient data, which includes patient data worth 15 million+ patients. The reality is, for most effective agentic AI orchestration of tasks in the native workflow, the real moat is not the agentic AI technology, but it is this AI training corpus that can be built if you have the patient data. Not just transactional access, asynchronous access, partial access to data, but true ownership of that data. Then you can convert that data into a truly longitudinal labeled action-aware dataset where you can link the clinical context to the actions taken and to the outcomes achieved from it. That enables truly the most effective agentic orchestration. Given that we would be in the EHR and we own the EHR, we can actually orchestrate all of those tasks in the native workflow synchronously. That really becomes a very, very compelling value proposition. We're very excited, continually about closing the TruBridge transaction and creating that additional vector of growth. The other by-product of that is useful for our core physician group market member is that 60%-70% of care delivered in rural hospitals is still outpatient care. A lot of the models that we build, including the SLM that we're going to build for rural healthcare and maybe multiple SLMs for different tasks with the rural healthcare, will actually apply in our large physician group market as well. Because like I said, the nature of the service provided in rural hospitals is largely outpatient in nature, which is what our physician group customers provide in our traditional market. As, as you know, we've put out a true north vision of taking our business at the confluence of executing as the only platform system of action in our traditional large physician group market and a truly integrated system of record and platform system of action in the rural healthcare market. We put our true north strategy out there. We believe that it'll take our EBITDA from that INR 1,000 crore odd mark LTM December 2025 to about INR 3,000 crore in FY 2030 and take us back close to zero net debt that we were getting close to this year. That's sort of our vision of the true north. Again, a big enabler of that is going to be this AI training corpus and the moat that we will create around it of being able to orchestrate agentically features in the native workflow and the SLMs that we will build that allow us to actually utilize the other foundational LLM models a lot lesser and build our own proprietary moat in these SLMs. In order to actually accelerate that journey of being able to build our own SLMs, we're also very excited to announce this additional acqui-hire that we are doing today, or rather did yesterday. A company called ARAI, which has been founded by two outstanding scientists really. Dr. Roland Haas, a gentleman of German origin that came to India 25 odd years ago, fell in love, and never left, I think. I think Roland will be happy with that description. Dr. Asoke Talukder, both associated with highly revered institutes over the course of their career. They built some very fine IP that is very relevant to our AI journey. As I was mentioning earlier, the way to solve for autonomy across the tasks in our 16 odd feature set is through neuro-symbolic models. Generative AI obviously relies more on the neural models, the deep learning models, and hence is more suitable for non-deterministic outcomes. Because some of these tasks will have deterministic outcomes, you'd need neuro-symbolic models where you can then constrain the outcomes of the generative AI through the reasoning that is available in the symbolic models that requires the usage of things like ontologies. Saransh, you can move to the next slide. Ontologies and knowledge graphs, which by the way, the team at ARAI has already built a bunch of knowledge graphs, and the IP associated with them for clinical reasoning. They've built clinical decision support systems. Really with this, we are going to be introducing the construct of what I call glassbox AI. What is the construct of glassbox AI? It's actually pretty straightforward. The idea really is that in healthcare, traditional AI doesn't really work because not only do you need to do the task, but you need to do the task in a transparent, traceable, and auditable manner because if the outcome of the task is anything less than accurate, it's very important to understand how the AI generated the outcome that it was suggesting. I'll give you an example of, you know, take medical coding as an example, right? In a traditional AI setup, a model might infer the codes directly from the clinical notes, the medical codes. Those codes might be close to accurate, but they might be missing some subtle critical details. In a glassbox AI system, the model instead maps the documentation to the standardized ontologies. It validates the relationships against the known medical knowledge. It also flags ambiguity when the confidence that the AI is producing in the code is low, which means then naturally get routed to a human reviewer when necessary if the confidence score is less. As a result of that, you get higher accuracy in coding, lower denials, and a clear audit trail. I think this sort of glassbox AI construct is going to be the real winner in the healthcare operating environment. I think really excited that the ARAI team advances our journey towards this transparent, traceable, and auditable AI with their proprietary knowledge graphs that they've already built. They really enable us to have a very scalable R&D talent pipeline. You know, they are basically talent magnets themselves. They're hands-on, even as their CEO and CIO. They write code today. You know, they have all of these research students around them that make for a very interesting recruitable talent base. Very excited about what they will be able to do to accelerate our journey. If you were to move to slide 25. In summary, we are paying about $1.2 billion in upfront cash for acquiring the IP. Saransh, you can move to the next slide. Obviously, you know, as they become employees of IKS, they'll have some ESOP-based incentives over the years. You know, like I was saying, they've already knowledge graphed several features in the IKS feature portfolio, if you would. The autonomous medical coding, the denials prediction and prevention within revenue cycle, and several other clinical decision support related knowledge graphs. It should lead to a significant acceleration of what we were trying to build from scratch and propagate this construct of this sort of glassbox AI, if you would. Oh, by the way, they become even more valuable assuming that we're able to close the TruBridge transaction in a few months from now because then that data flywheel that I was talking about, that AI training corpus is what they'll be able to accelerate our journey to that dramatically and help us, you know, build these SLMs that I'm talking about that reduce our reliance. If you can move to the next slide, Saransh. Reduce our reliance on the more commercially externally available foundational models because over a period of time, that cost of compute is going to be important. The proprietary knowledge that we will build on our SLMs will become our strategic moat over a period of time. Super excited to announce the acquisition and integration of ARAI as well. I'll just spend a last couple of minutes on something that is very dear to our hearts, might not have immediate financial consequences for you all as investors, but I'll take a minute, is the IKS Cares Foundation, which was a construct launched a few years ago because as you know, we employ about 1,900+ clinically trained staff, most of which are doctors. We said, "What is a way for us to do CSR in a way where these doctors, in addition to enabling U.S.-based physicians, can also get connected back to the practice of medicine and in the process actually earn more and we can do something good for society?" We've actually launched the IKS Cares Foundation, which leverages our own internal clinical talent on weekends and holidays to run medical camps in financially underprivileged sections of society predominantly in Maharashtra and Telangana. We've taken three major causes that we are solving for through these camps. One is anemia in women and children, which we've been shocked to learn the incidence of high incidence of anemia in women and children. Second is, of course, diabetes, which is a national pandemic. The third is just oral hygiene for underprivileged sections of society. Some of the numbers that we've been able to achieve are really stunning with 15,000+ screenings that we've done in our 1st year and a half of existence. Which is a massive unmet need. We've done this over Saransh, if you can move to slide 31. 194 medical camps where overall 45,000+ people from underprivileged sections of society have been screened. 15,000+ of them were actually diagnosed as anemic, and 42% of those were transformed from anemic to non-anemic levels. Then there's a 110 odd follow-up camps where medications have been provided. In addition to that, recently we started these dental camps where we've done 15 odd camps and nearly 1,800 dental screenings and 900+ dental treatments. A very important cause that is very near and dear to us that allows us to do good in India, Indian healthcare, even as we are enabling a lot of efficiencies in U.S. healthcare. With that, thank you for your time. Again, I'll round up by saying a strong quarter and a year of performance and a lot of exciting things to look forward to. First of, shall we open the floor for question and answer? Yes, please. Thank you very much. We will now begin the question- and- answer session. Anyone who wishes to ask a question may press star and one on their touchtone telephone. If you wish to remove yourself from the question queue, you may press star, then two. Participants, you are requested to use handsets while asking a question. Ladies and gentlemen, we will wait for a moment while the question queue assembles. A reminder to all, you may press star and one to ask a question. We will take the first question from the line of Anil Nahata from Parami Financial. Please go ahead. Good morning, Sachin and team. First of all, congratulations for a great acquisition of TruBridge. The way the deal is, I mean, equal size deal, completely financed by debt, I guess, which will take around three, four years to pay down the debt while we can do anything else. I guess we are all in into that. As they say, "When you are all in, you better get it right." All the best for that. My first question is on the opportunity which I believe may be coming in the U.S. market, which is CommonSpirit Health. I mean, they have terminated their deal with Tenet, they are the one of the largest healthcare provider there and having multiple Epic instances. At the same time, I see that we have been very Epic active on the Epic marketplace, where we have now sort of seven listings, against two which was a couple of quarters back. How are we gearing up for these kind of opportunities, and is there a huge play for us? Anil, thank you for your kind words, first of all. Appreciate it. Lots of work, good work ahead of us. You know, it's hard to comment on individual opportunities, as you can imagine, based on the confidential nature of some of these pursuits. Happy to note that CommonSpirit is very much on our radar and they are in the process of figuring out the specifics of their own strategy as they have bolted out of the Tenet arrangement. In fact, we have some past history of working with several, call them ministries within CommonSpirit. As their own strategy becomes clearer, it'll be interesting to see how that plays out for us. I think your observation is very appropriate and timely that it could present a pretty large opportunity. Thank you for that, Sachin. My second question is, if I go back to your last quarter's con call, you did mention that you are creating a parallel system just like we have the platform in the ambulatory space for the acute space. Came the announcement for TruBridge, which is basically in the acute space. This sort of development you were mentioning, it will take us two years to complete to where we are in the ambulatory space. How will the product development, the tech stack now happen once TruBridge and IKS is integrated? Would IKS stack be taken there, or how is it going to happen? Just if you can do a slight deep dive into that. Thank you so much. Sure, Anil. Happy to do that, obviously. The way to think about it is, remember I was saying that 60%-70% of the care delivered in rural hospitals is outpatient care. What IKS has done in its traditional large physician group market is predominantly outpatient care. A lot of the technology that we have built in our platform system of action for all of these tasks actually becomes naturally applicable to that rural healthcare market because of the service mix that they have, because they don't have secondary, tertiary, quaternary capabilities like sophisticated hospitals. Yes, I think our platform system of action from our physician group market will be very relevant in the rural healthcare market, even though there is 0 actual customer overlap. Now, of course, the holy grail here will be in our traditional market, that platform system of action had to asynchronously interact with the system of records like Epic, eClinical, Cerner, etc. They would access the data in the electronic health records based on API calls. We would get partial access to the data just enough to orchestrate that transaction. In the world that we are going to, if we are able to close the TruBridge transaction successfully, and as we modernize their EHR from a legacy COBOL to a Postgres, what we'll be able to do is now integrate our system of action deeply into the electronic health record. With the access to data, convert that data into the AI training corpus, and using that AI training corpus which is necessary for this agentic orchestration, to be able to do that agentic orchestration synchronously in the native workflows of the EHR. Think of it as still a good two year type product journey. Now, some of the features of our platform system of action will be able to integrate faster into the TruBridge data. Others might take longer depending on the specifics of that features. I think you're exactly right that the TruBridge acquisition puts us in a position where we are able to orchestrate several features of our traditional platform system of action in the human healthcare market, such that we'll be only integrated platform system of action and system of record. Thank you. We will take the next question from the line of Nitin Jain from Fairvalue Equity Advisory. Please go ahead. Yeah. Thank you for the opportunity. What I would like to know from the management is what type of risks do you envisage you might face two, three years down the line when AI becomes more prevalent and coding becomes even more cheaper? How are we preparing for that? Nitin, obviously the better part of the presentation and the dialogues were actually geared around that, obviously. Thank you for your question. Suffice to say that obviously we are building our own AI. The fact that AI makes coding easier or cheaper is awesome for us because we don't get paid to write code for others. We write our own code, and our own technology orchestrates these actions. As AI makes code generation cheaper and more reliable, that's a huge tailwind for us. That's not a headwind for us. As it relates to how are we leveraging the AI that we're building, that is what I was talking about, where because now with the TruBridge acquisition, we will have access to this data moat and the AI training corpus that will get built from it. All the AI that we are building will actually become a lot more relevant and usable much faster in the native workflows of the electronic health record. Hello? Yes, please. Hello. Yes, Nitin, you're audible. Please proceed. Yeah. Yeah. Thank you. Thank you for the clarification. My next question is, the management mentioned that, we have been growing very well for last almost five to six quarters now. Given that we have a high base going into the next year- Yeah. ...at what point of time do we think this base will catch up and our growth might taper down a bit? Nitin Jain, as you know that, I've said this all through the time we went public, we are not giving guidance, and we won't give guidance. You know, this is not a linear journey. Not only do we have a track record of six quarters, but if, Saransh, you can put that slide out there. We have a track record of 10 years that we can demonstrate in our financial performance. That is nothing to say that history is not always a predictor of the future. All I can tell you is there's a very large TAM, a very small outsourced TAM relative to that large TAM that is growing at 12%. I think we've built a business that has the right to win in this market. Yet I'm not in a position, Nitin, to predict that exactly what our growth rate is going to be quarter-on-quarter. Having said that, we've given a true north target to ourselves of tripling our EBITDA from trailing 12 months, calendar 2025, of about INR 1,000 crores to about INR 3,000 crores in FY 2030. I wish I had a better ability to predict exactly what's going to happen every quarter-after-quarter, and when the growth will accelerate or slow down. I don't, unfortunately. I think, at the confluence of our past growth track record and the defensibility of the model that we've built, hopefully, you know, we're putting ourselves in a position that over a medium to long-term timeframe, we can emerge as a leader in this space. Thank you. We will take the next question from the line of Rohit Thorat from Axis Capital. Please go ahead. Thank you for the opportunity. In your opening comments, you highlighted that your revenue growth is growing faster than your headcount growth. Aren't you seeing any pricing pressures from clients to actually pass some of the productivity back to them? Because a lot of IT services companies and BPO people have also highlighted the fact that they are seeing AI-led productivity deflation of around 2%-3% in FY 2027. Are you witnessing any similar pressures or not, you haven't encountered any such pressures yet? Thank you for the question. You know, as I've been always saying, our model is slightly different from or maybe fundamentally different from traditional IT services and BPO services, where they are getting often paid based on the number of people they deploy or the number of transactions they process. Our pricing model has always been outcome-based, and a percentage of the customer's revenue is how we get paid. Obviously in that model, sir, you'll appreciate that it gives us a very differentiated ability to be able to capture some of the efficiencies in our margins. Having said that, over a period of time, naturally, even on a percentage of revenue basis. Can we expect a minor deflation in the percentage of revenue pricing that we get? Yes. Have we seen that deflation already in some of our features that large health system-owned groups buy individually? Absolutely, yes. For example, like I was mentioning, our Ambient AI scribing product, we have seen deflation in pricing. I will say that we will see more deflation in pricing of features that are more easily autonomizable and less deflation of pricing in features that are not easily autonomizable, right? At the confluence of that is also one of the reasons that the winner over a period of time is going to be a platform system of action versus what we call the point solution system of action. When you're a point solution system of action, the proclivity of that pricing getting commoditized is much higher than when you have a consolidated platform pricing for the customer. That is why that platform approach is very, very important to our future. Because, one, the platform makes life a lot easier for the customer, and second, it has its inherent benefits for the entity that's providing the platform as well. I think fundamentally different paradigms. Of course, I mean, the history of any product, sir, as you know, is that as products keep getting better, costs come down, or prices come down. The winners in the market are able to mitigate that pricing through both intelligent pricing mechanisms and managing their own costs more effectively. So far, we've been able to, and we feel like we're continuing to build a model where we will have a significant advantage over traditional IT service and BPO models. Yeah. Thank you. Thank you for answering that. Just two more bookkeeping questions from my side. First is on the ESOP cost, which has seen sharp increase in the last two quarters. What should be the steady quarterly run rate which we should see going forward? The second question is regarding ETR. Nithya mentioned that ETR should be 22% in FY 2027. Is that just for the core IKS business, or would it be on a consolidated basis for IKS and TruBridge's businesses combined whenever the transaction completes? So I'll let- Uh- Nithya respond to the second one. Maybe, Nithya, you can answer both. Yeah, sure. On ETR, the guidance is only for IKS. It's not for the pro forma IKS and TruBridge entity. We'll talk to you about it when we do the consolidation. On ESOP cost, our ESOP cost will trend in line with our aspiration to continue to expand our technology team as well as our leadership team. ESOP is a tool that we continue to use to be able to align our employees' incentives with shareholder value creation. Sachin, if you want to add on the ESOP question. Yeah, just only thing I'd add is that just like any other financial parameters, we don't give guidance on any one parameter. Like Nithya said, it is a very important tool. It is a competitive market. As a leader in the market, we need to make sure that the most important contributors to our business, even in an AI world, which is our people, are tucked in and incentivized to continue to drive our leadership position. ESOP will continue to be a reality. As we close and integrate TruBridge, we will obviously be incentivizing a lot of the key leadership that is coming from TruBridge as well. You know, we try not to give any guidance around that specifically. Thank you. Thank you for answering my questions. Thank you. We will take the next question from the line of Dev Thacker from ithoughtPMS. Please go ahead. Hello. Thank you for the opportunity, and congratulations for the great set of numbers. My question was regarding the TruBridge acquisition, where COBOL to SQL is listed as the most important item. Could you please expand on that? What challenges are we seeing? Of the 700 client, any rough number how many of them are on the COBOL, and how important it is for the RCM expansion? Great. Thank you for the question. First of all, obviously, you know, the transaction isn't closed now, so until the transaction closes, we can't really affect anything. The strategy, which by the way they have already started, is the migration from COBOL to Postgres. That is critical to move them from the legacy system to eventually a cloud-native AI-first system. In a traditional world, the COBOL to Postgres migration would have been a real challenge because, as you know, in the COBOL world, a lot of the business logic is embedded in the database layer, a lot of it is embedded in the UI layer as well, and reverse engineering that business logic out of those layers becomes a huge challenge. In this case, as AI has become much more prevalent, AI does a lot of that reverse engineering of the business logic, which makes the migration remarkably easier than it used to be in a traditional world. Having said that, it is still a significant migration, and it will take us a while to get our arms around it and do that completely. The good news is we're doing it in a modular way, so there are several modules of the EHR that might be in a Postgres world before the others are. That'll accelerate our progress. Having said all that, to your question of the RCM opportunity. The RCM opportunity is kind of independent of that migration. Once that migration happens and we start converting the data to an AI training corpus, obviously that will have impacts on our ability to make the RCM more efficient through agentic orchestration of several tasks. Today, the world that we're living in. The reality of that is that there is a lot of RCM that is still happening manually, and hospitals are struggling with it. Prior to IKS, their RCM business across their 700+ hospitals on a gross level is growing at 15%-16%. At a net level, it's only growing at 10%, the RCM business, because they're not able to execute efficiently leveraging technology, leveraging the India model. That's where IKS's core expertise will come in, transform that RCM piece. In parallel, the COBOL to Postgres migration will happen, and the creation of the data flywheel will start to happen. This will then allow us to get agentic in several of the tasks within the RCM system of action. This is a good 18- 24 month process before we can be in a fully integrated system of action and system of record that allows for agentic orchestration and native workflows. That doesn't impede us from continuing to do what needs to be done to improve performance in RCM, as well as, proliferating that RCM into, you know, beyond the 250, 300 of their customers that are already on RCM, EHR customers, proliferating the RCM model to the other customers. Got it. Thank you so much for the detailed clarification. Next question could be, was a bit elementary. When we look at the contribution of revenues from top 10 clients on a quarterly basis, the percentage contribution is much higher as opposed to seen on a annual basis. Like, how should we see this? Because what I want to understand was the overall growth trajectory. Like you mentioned, AQuity cross-selling strategy has been revamped. Like, going forward, should we see the overall growth in among all set of clients? Nithya, you wanna take that? I think it's best if you look at it more on a year-on-year basis. That gives a more truer reflection of the underlying business growth. There will always be quarterly variances, and there is some seasonality to some parts of our businesses as well. Please look at it on a year-on-year basis. Thank you. We will take the next question from the line of Madhuchanda Dey from MC Pro. Please go ahead. Hi. I have three questions. The first question is, you have grown at the rate of 15% in USD terms. Is it possible to break up that growth between volume and value? Hello? Yes, we can hear you, ma'am. Your question is how to break up growth between volume and value. We tend not to do that. Obviously, that changes on a very, very frequent basis. It's very hard to do that, ma'am. Okay. I mean, we just wanted to understand what kind of value growth happens annually, I mean, in an existing contract of yours. Like I said, it's not a natural linear number, ma'am, because the volume growth is a function of many factors. Like let's say you take a large physician group that you're working with. There will be years in which they will have the same number of physicians year-on-year, and the volume growth is just driven by the patient footfall. There'll be other years where the number of physicians itself has grown, and hence the volume growth is driven by that. There are customers in which there might be 1,000 physicians, but only 500 of their physicians are using our product. Now in a year, the 500 could grow to 750, and that drives a different type of volume growth. There could also be increase in the number of features that the physicians are using of our platform, the same number of physicians, and that could lead to a different type of volume growth. That's why, ma'am, it's very hard to isolate the specifics of perhaps what you're asking, if I understand it correctly. Okay. Got it. I have another housekeeping question before I move to my third question, which is, you know, in your latest presentation, the contribution from top 10 customers is 37% for the fiscal 2026. Whereas if I look at the quarterly numbers, there are 43% in Q1, 45% in Q2, and 48% in Q3. If you could help us understand this number a little properly. The gentleman before this had the same question. I would recommend investors to look at these numbers on an annual basis. There always tend to be quarterly variances in terms of in terms of our customers. As I mentioned before, there also tends to be seasonality in particularly the revenue optimization or the RCM business. That tends to contribute to the quarterly variances. I think the best right number to look at would be on an annual basis. Whereas you can appreciate both our top 10 and top five have grown, have grown strongly. Thank you. We will take the next question from the line of Krish Jain from NAFA Asset Managers. Please go ahead. Yeah. I hope I'm audible. First of all, congratulations on a great year, and I hope this growth continues. My question is more about the industry as a whole. Just like a few days back, the Carlyle Group announced their, what, two companies which are, you know, in the RCM space. This is not the first time I've heard a PE deal happening. Two or three other big PE firms have bought Indian RCM players, you know, one and a half years back. I want to understand if my understanding of, you know, consolidation happening in the industry and more and more PE firms getting interested in this space is correct. What is your comment about, you know, the competitive landscape in the medium and future, medium and long term because of these acquisitions happening? Hi, Krish. Thank you for the question, and you and me both hope that the growth continues even as we work on it. Real quick, on competitive, like I was saying, you know, Krish, when you have such a large TAM and the outsource TAM is so small relative to the TAM and growing so significantly, obviously you have to expect the competitive intensity to increase, and you have to expect that there will be more and more capital that will enter this space chasing the opportunity. None of that is a surprise. There is a lot of private equity capital. In fact, the statistic is, order of magnitude. There has been about $50 billion invested in healthcare IT alone, which is all of this space over the last four years. There is a lot of capital across the globe chasing this opportunity. This $50 billion I'm talking about is predominantly just for the U.S. healthcare market. Having said that, the way to think about competition, like I had said at the beginning of the conversation, is there's three genres of competitors. There's a finite set of system of record companies, the EHR vendors. There is a massively growing set of point solution systems of action, which is the easiest way to enter the market is build one feature or one action. There is this, call them rare beachfront properties, perhaps, although that sounds a bit self-serving like ours, where, you know, we are building a platform comprehensive system of action that takes all the features that the provider should not be straddled with, right? I think the fastest growing category of competitors is in that point solution systems of action. Because again, the entry barriers in that genre of competition is the smallest. That's where you see that, you know, the deal you referenced with Carlyle, it's a point solution company with pure focus on RCM. That doesn't make them a good or a bad company. I'm not commenting on the quality of the competition. I'm just saying that is the genre that will see the maximum competitive intensity. Now, we could be right or we could be wrong, but our contention is, I call that word point solution hell, because imagine if a large health system has to hire 15, 20 different vendors or even 10 different vendors across these 15, 16 tasks to do them well. In a scenario like that, how can they possibly hold any one vendor accountable? They are left with the baggage of integrating everything, right? For me, very early in our journey, we had determined that we don't want to be a point solution vendor. We want to be a full platform system of action, and that's what we are betting on. That is not to take away from the fact that there will be a constant increase in competitive intensity in that point solution system of action space. Yes, there will also be continued consolidation in that space because as that space gets more and more commoditized, which is inevitable, then your only way to fight that commoditization is to scale and consolidate. That's why one is continuing to see that. Hope this helps. Thank you for the detailed answer. That really helps a lot. Forgive me, but I was a little late to the call, so maybe this question has been answered. What is going to be a strategy in the future for acquisitions? Are we going to see more TruBridge's acquisition, which is basically doubling revenue, or are you looking at, you know, very focused AI players that you want to buy, small focused players like the recent acquisition? Good question. Thank you again. I mean, I don't think we are looking for additional TruBridge. As you know, if we are able to consummate the TruBridge transaction, we will end up with about 3x leverage of EBITDA at the time of close. Obviously our focus will be to deleverage the balance sheet through the internal accruals and the strong cash flows that we anticipate generating through the combination. Having said that, I think there will be some continued opportunities for tuck-in type deals, some much smaller in nature like the deal we announced today with ARAI, that fundamentally accelerate our capability from an AI perspective. There might also be some tuck-in type opportunities as it relates to certain point solution vendors, like I was discussing earlier, that will end up having found sort of a space where they have hit their ceiling because of the commoditization of the point solutions, and those might create certain opportunities. A transformative acquisition like TruBridge, first of all, comes very rarely. And, second, you know, obviously we want to continue to stay disciplined about not over-leveraging the balance sheet and/or not unnecessarily diluting shareholder AQuity through raising AQuity. Generally, I don't anticipate more transformative acquisitions anytime soon. Small tuck-ins that are highly accretive, certainly we'd be open to those. Thank you. We will take the next question from the line of Dev Thecker from ITOT PMS. Please go ahead. You may proceed with the question. Hello. Thank you for the opportunity again, sir. Sir, I had just one request. The metrics and the presentations are very detailed, but if possible, could you also provide breakup of revenue in terms of single solutions and multi solutions, because that would be very helpful. Yeah, we've never done that. Remember the basic thesis of our business is that the winners are the platform constructs, right? Over a period of time, we anticipate the bulk of our revenue migrating to platform constructs, even in cases of large health systems where we might start and land with point solutions and expand to the platform. We ourselves are resisting the temptation of getting too caught up in revenue contributions for individual solutions because that is at odds with the identity of the organization in and of itself. I apologize, my friend. Got it, sir. Thank you. Thank you. We will take the next question from the line of Chirag Kacharia from Motilal Oswal Financial Services. Please go ahead. Hello, am I audible? Yes, you're audible. Please proceed. You mentioned about the electronic health records that, all the system in the U.S. started in the year 2000, and that they remain, you know, just a database collector of the patient information. Chirag, I'm sorry. You're very faint here. Can you speak a bit louder? Sorry, Chirag. Yeah. My question is on the electronic health records. As you mentioned, most of these players in the U.S. started in the year 2000 or before that, and they remain, you know, just a collector of the patient database and all. The entity which we are acquiring, they also have an EHR presence, right? If you look at their past historical performance, that is largely stagnant, okay? How are we going to, you know, increase the growth trajectory of that vertical? In our existing IKS offering, what% is coming from EHR? Is there any overlap in the services of this entity and TruBridge? How are we going to, you know, increase the growth, revenue growth for this EHR? I apologize, Chirag. I really struggled to catch the question. Nithya, did you catch it clearly? bits and pieces. I think his question is around TruBridge's EHR that we're acquiring and the fact that that business has been stagnant. Yeah. I think what do we intend to do about it once it's in our hands. Okay. Thank you for the question. Yes. You know, like we've said, the EHR market is a mature market where in most of the EHR sub-segments, like rural healthcare is a $162 billion sub-segment. You know, they've already reached a maturity where there it's a two or three vendor market, and there is not much fluctuation. For example, in the rural EHR space, rural hospital space, there are 2,200 hospitals, and TruBridge's EHR is already in 700 of those hospitals, right? Nearly 35% market share already exists. What one should not anticipate is some dramatic growth coming from the EHR segment in and of itself. Having said that, in the case of rural healthcare, the two vendors that are most prevalent are TruBridge and a vendor called MEDITECH. There's also a third vendor called MEDHOST, but TruBridge and MEDITECH are the most prevalent. The EHR that is able to modernize itself most rapidly and is able to build an integrated system of action eventually might have some market share opportunity as well. That will not be our focus. Our focus will not be to capture greater EHR market share in the next two to three years. Our focus will be to modernize the EHR, integrate our system of action in it, and the real growth will be to cross-sell the system of action into the EHR customer base. Remember I said, only 250 odd of the EHR customers that TruBridge has. Yeah. Only 250 odd have the RCM offering. First is you have a 450+ customer market just for the RCM system of action. There are other components of our system of action because we have 16 odd features. RCM is just six or seven of them, right? We'll also cross-sell all of those features into the TruBridge EHR install base. Think of the growth vectors really as the cross-sell of the system of action in the EHR install base. As we modernize the EHR and we've integrated the system of action, could we ignite another vector of growth where we actually capture additional EHR market share? Perhaps. I wouldn't be banking on that as the thesis here. Okay. Thank you. Thank you. A reminder to all, you may press star and one to ask a question. Thank you very much. As there are no further questions from the participants, I now hand the conference over to Mr. Saransh Mundra for closing comments. Thank you, and over to you, sir. Thank you. Thank you, everyone. Please reach out if you have any further questions. Thank you so much for attending. Thank you, everyone. Good luck. Thank you. Thank you, members of the management. On behalf of ICICI Securities, that concludes this conference. Thank you all for joining with us today, and you may now disconnect your lines. Thank you.